Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2017) 49 EP1094 | DOI: 10.1530/endoabs.49.EP1094

1‘C.I.Parhon’ National Institute of Endocrinology, Bucharest, Romania; 2‘Carol Davila’ University of Medicine and Farmacy, Bucharest, Romania; 3Clinical Institute Fundeni, Bucharest, Romania.


The relationship between the level of genetic variation in CYP17, PSA genes and prostate cancer has been extensively studied but the results are still unclear. A 450c17a (CYP17) polymorphism A1/A2 was described to be significantly associated to prostate cancer. A SNP in the promotor PSA gene is an A to G substitution at position −158 (G158A) was proposed to interact differently with AR, thereby modifying the expression pattern and occurrence of prostate cancer.

Objective: The aim of the study was to investigate the association between CYP17 and PSA gene polymorphisms with advanced prostate cancer.

Subjects and methods: The study was conducted on 48 patients with advanced prostate cancer (Gleason score > 7) and 13 benign prostate hyperplasia subjects. Patients were enrolled after they gave their informed consent. DNA was isolated from prostatic tissue with PureLink Genomic DNA (Invitrogen). Genotyping of the A1/A2 and G/A polymorphisms in the promoter region of CYP17 and the PSA, respectively, were determined by a PCR–RFLP assay. PCR product was digested with restriction enzyme NheI (PSA G-158A) and MspA1I (CYP17). Preoperatory serum PSA was assayed by immunochemiluminescence.

Results: Genotype distribution differ for PSA G-158 between the prostate cancer and the control group (25% GG, 25% AA, 50% AG vs. 8% GG, 23% AA, 69% AG) and for CYP 17 (36% A1, 45% A1A2, 19% A2 vs. 22% A1, 64% A1A2, 14% A2). The frequency of A1 allele was 0.41, and 0.59 for A2 allele. In control group the frequency of A1 allele in population was 0.46, for A2 allele the frequency was 0.54. Neither CYP17 nor PSA polymorphisms associated with prostate cancer. Serum levels of PSA did not differ between genotypes.

Conclusion: In our study groups CYP17 and PSA gene polymorphisms did not significantly associated with prostate cancer or serum PSA levels. Further studies are needed on larger cohorts.

Acknowledgement

This work was funded by UEFISCDI grant no. 192/2014

Volume 49

19th European Congress of Endocrinology

Lisbon, Portugal
20 May 2017 - 23 May 2017

European Society of Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches.

My recently viewed abstracts